Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02720198 · ClinicalTrials.gov registry record · Phase 3
Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD
A Phase 3 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT02720198 is a Phase 3 study that has completed, run by Duke University. The registered enrollment target is 60 participants.
The verdict
NCT02720198, a Phase 3 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study's primary objective is to compare the efficacy and tolerability of switching patients with inadequate relief on generic SSRIs to levomilnacipran versus adding a new treatment (quetiapine) to the participants' existing treatment with people diagnosed with depression (major depression disorder). The secondary objective is to examine the response and remission rates following the switch from a generic SSRI to levomilnacipran ER and augmentation with quetiapine along with examining changes in neurocognitive and apathy measures after the switch.
Interventions
- DRUG Quetiapine
- DRUG Levomilnacipran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-01-23 |
| Est. Completion | 2018-06-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02720198
The ClinicalTrials.gov registry entry for NCT02720198 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quetiapine is the first listed.
NCT02720198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02720198 about?
NCT02720198 is a clinical study titled "Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD". This study's primary objective is to compare the efficacy and tolerability of switching patients with inadequate relief on generic SSRIs to levomilnacipran versus adding a new treatment (quetiapine) to the participants' existing treatment with people diagnosed with depression (major depression disor...
What is the current status of trial NCT02720198?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2017-01-23. Estimated completion is 2018-06-12.
What interventions are being tested in trial NCT02720198?
The interventions under investigation include: Quetiapine (DRUG), Levomilnacipran (DRUG).
Who is sponsoring clinical trial NCT02720198?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.